Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/MESO
icon
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Mesoblast Limited (MESO) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Read full analysis

Key Stats

  • Market Cap
    $1.75B
  • Volume
    239,027
  • Sector
    Health
  • 52W High
    $20.96
  • 52W Low
    $13.19
  • Typical Hold Time
    15 Days
  • Enterprise Value
    $1.83B
  • Div Yield
    -
  • Trading Activity
    -
$14.29
52W Low: $13.19
26 Jun 2026
52W High: $20.96
09 Jan 2026

Track Mesoblast Limited (MESO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Mesoblast Limited has traded between a low of $13.19 and a high of $20.96, highlighting its annual price range. Buy and sell Mesoblast Limited shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Most Recent News

Content is generated by Aura AI

ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.

ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Market News
57 minutes ago
Zenatech, Inc.
Bullish
news icon
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.

The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

Market News
2 hours ago
Rosen Law Firm
Bearish
news icon
Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.

MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

Market News
2 hours ago
Mannkind Corporation
Bullish
news icon
New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $1.75B
  • Volume
    239,027
  • Sector
    Health
  • 52W High
    $20.96
  • 52W Low
    $13.19
  • Typical Hold Time
    15 Days
  • Enterprise Value
    $1.83B
  • Div Yield
    -
  • Trading Activity
    -
$14.29
52W Low: $13.19
26 Jun 2026
52W High: $20.96
09 Jan 2026

Track Mesoblast Limited (MESO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Mesoblast Limited has traded between a low of $13.19 and a high of $20.96, highlighting its annual price range. Buy and sell Mesoblast Limited shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!